Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes, Aman Chauhan, Anna Spreafico, Karl D Lewis, Debora S Bruno, Olivier Dumas, David F McDermott, James F Strauss, Quincy S Chu, Lucy Gilbert, Arvind ChaudhrySee the full list of authors
20 November 2024
Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastasesChristopher Fife, Jennifer Williams, Fiona James, Scott Gregory, Tereza Andreou, Ashley Sunderland, Clive McKimmie, Rebecca J Brownlie, Robert J Salmond, Samuel Heaton, Fiona Errington-Mais, Zarnaz Hadi, David R Westhead, Marlous Hall, Alexander DavieSee the full list of authors
17 November 2024
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancerShipra Gandhi, Ronald T Slomba, Cayla Janes, Victoria Fitzpatrick, Janine Miller, Kristopher Attwood, Giorgio Ioannou, Sinem Ozbey, Igor De Souza, Vladimir Roudko, Prasanna Kumar, Suresh Kalathil, Kathleen M Kokolus, Jianming Wang, Eduardo Cortes GomezSee the full list of authors
14 November 2024
Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomasLilit Karapetyan, Aofei Li, Danielle Vargas De Stefano, Hassan M Abushukair, Ayah N Al-Bzour, Andrew Knight, Caroline Layding, Hong Wang, Jin Xu, Jiqiang Yao, Xiaofei Song, Marion Joy, Jonathan Nguyen, Carlos Moran-Segura, Sabrina BrunoSee the full list of authors
12 November 2024
Correlation of safety and efficacy of atezolizumab therapy across indicationsGonzalo Durán-Pacheco, G Scott Chandler, Vidya Maiya, Mark A Socinski, Guru Sonpavde, Javier Puente, Laurent Essioux, Corey Carter, Jose Vicente Cardona, Rajat Mohindra, Jarushka Naidoo
12 November 2024
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunctionDavid W Vredevoogd, Georgi Apriamashvili, Pierre L Levy, Sanju Sinha, Zowi R Huinen, Nils L Visser, Beaunelle de Bruijn, Julia Boshuizen, Susan E van Hal-van Veen, Maarten A Ligtenberg, Onno B Bleijerveld, Chun-Pu Lin, Judit Díaz-Gómez, Santiago Duro Sánchez, Ettai MarkovitsSee the full list of authors
7 November 2024
Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid culturesJulijan Kabiljo, Anna Theophil, Jakob Homola, Annalena F Renner, Nathalie Stürzenbecher, Daphni Ammon, Rebecca Zirnbauer, Simone Stang, Loan Tran, Johannes Laengle, Askin Kulu, Anna Chen, Markus Fabits, Velina S Atanasova, Oliver PuschSee the full list of authors
4 November 2024
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBaseRoberta Noseda, Francesca Bedussi, Valentina Giunchi, Michele Fusaroli, Emanuel Raschi, Alessandro Ceschi
3 November 2024
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacySantiago Acero-Bedoya, Emily F Higgs, Anna C Martinez, Ruxandra Tonea, Thomas F Gajewski
26 October 2024
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trialZhiming Li, Wenqi Jiang, Hui Zhou, Hong Cen, Mingzhi Zhang, Fangfang Lv, Qingyuan Zhang, Xiuhua Sun, Lihong Liu, Yunhong Huang, Haiyan Yang, Sujun Gao, Chuan He, Wei Yang, Wenyu LiSee the full list of authors
24 October 2024